An interventional study of Emotional skills and Relaxation and talking group in Digestive System Neoplasms and Thoracic Neoplasms, sponsored by University Hospital, Lille. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-10.
Sponsored by University Hospital, Lille · Not applicable, Interventional, and Supportive care
Among 31 studies in Digestive System Neoplasms with a site in France — 5 open to participants now, 7 under way, 1 of them phase 3. Digestive System Neoplasms · France.
Among the 31 studies in Digestive System Neoplasms with a site in France, this one is the 22nd largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2017, is one of 7 with no phase, and was the 20th registered.
195 studies on the registry are indexed under Digestive System Neoplasms; 57 are open to participants now.
Browse Digestive System Neoplasms studies →5 of the 31 studies in Digestive System Neoplasms with a site in France are open now. Recruiting first, the newest first:
University Hospital, Rouen · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Pfizer · Sites in France, United States, Argentina and 14 more countries
Ages 18+
Turning Point Therapeutics, Inc. · Sites in France, United States, Australia and 16 more countries
Ages 12+
Institut du Cancer de Montpellier - Val d'Aurelle · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 52 Digestive System Neoplasms studies recruiting now, 27 (52%) set no upper age limit and 17 (33%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 9
First in 2002; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 50 across 156 interventional studies indexed under Digestive System Neoplasms.
Median enrollment 109 across the 26 interventional studies, 300 across the 5 observational. Of the 24 that completed or were terminated, 7 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 31 have an industry lead sponsor. The 10 most frequent:
University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
University Hospital, Lille has 2 studies filed under Digestive System Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Digestive System Neoplasms with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07739121Assistance Publique - Hôpitaux de ParisBenchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations | 2026-12-31 |
| NCT05063565Boston Scientific CorporationTheraSphere With Durvalumab and Tremelimumab for HCC | 2027-06 |
| NCT05238922Incyte CorporationStudy of INCB123667 in Subjects With Advanced Solid Tumors | 2027-07-27 |
Among the 31 studies in Digestive System Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to test whether a short educational intervention about emotional skills can improve survivor cancer patient emotional skills and quality of life. Half of participants will follow the educational intervention about emotional skills, while the other half will practice relaxation followed by a non-directive talking group. The educational intervention should give better results on patient emotional skills and quality of life than the control group.
After the end of treatments, cancer patients face a difficult time because it is expected that they return to normal, but at the same time they still have to struggle with the aftermath of cancer and fear of recurrence. This is why there is room in this period for an intervention designed to help patients to cope with their emotions. . Patient emotional skills are patient abilities to identify, express and manage their emotions for the best possible psychological adjustment. In general population, emotional skills have been shown to be highly related to a better quality of life. In this randomized controlled study, bronchopulmonary and oesogastric cancer patients between 6 months and 2 years after the end of treatments will undergo either the emotional skills intervention (intervention group) or the relaxation group (control group).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 group sessions where patients are going to learn how to identify, express and regulate their emotions
Behavioral: Emotional skills
3 group sessions where patients are going to follow relaxation instructions and after a non directive talking group about cancer
Behavioral: Relaxation and talking group
2-hour 3 group sessions
Also known as: Emotional intelligence
2-hour 3 group sessions
Change in patient emotional skills from baseline to 15 days after intervention
Variation of patient-reported Short Profile of Emotional Competence (S-PEC)questionnaire score from baseline to 15 days after the intervention (between 1 and 3 months)
Time frame: Baseline and 15 days after the end of the intervention
Patient emotional skills long term
Variation of patient-reported PEC (Profile of Emotional Competence) questionnaire score
Time frame: T1 (15 days after the end of the intervention) and T2 (2 months after T1) : 2 months
Quality of life by Medical Outcome Study Health Survey Short Form-36 (MOS SF-36)
Patient-reported health-related quality of life using the Medical Outcome Study Health Survey Short Form-36 (MOS SF-36)
Time frame: Baseline (T0), 15 days after the end of the intervention (T1), 2 months
Patient participation in workshops
The percentage of patients who have attended the 3 group sessions
Time frame: Between 2 weeks and 2 months
Patient adherence to exercises to do at home between sessions
The percentage of patients who have performed the suggested exercises at home between sessions
Time frame: Between 2 weeks and 2 months
Patient satisfaction
Patient-reported satisfaction regarding the intervention using and ad hoc questionnaire
Time frame: T1 (15 days after the end of the intervention) and T2 (2 months after T1)
Ran from Oct 2017 to primary completion in May 2019, 18 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.